Latest "Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel" News Stories

19:57 EDT 20th September 2018 | BioPortfolio

Here are the most relevant search results for "Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel" found in our extensive news archives from over 250 global news sources.

More Information about Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel for you to read. Along with our medical data and news we also list Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel Clinical Trials, which are updated daily. BioPortfolio also has a large database of Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel Companies for you to search.

Showing "Tavocept BNP7787 combination with cisplatin either docetaxel paclitaxel" News Articles 1–25 of 858

Thursday 20th September 2018

The Economics Of Drug Shortages: US FDA Seeks Broad Input

FDA is planning series of stakeholder meetings to identify new approaches to drug shortages, with particular interest in defining “essential”...   

Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes

Bagsværd, Denmark, 20 September 2018 - Novo Nordisk today announced the headline results from PIONEER 10, a phase 3a trial with oral semaglutide vs once-weekly subcutaneous dulaglutide, both in combination with one oral antidiabetic drug in Japanese adults with type 2 diabetes. Oral semaglutide is an investigational GLP-1 analogue taken once daily as a tablet. The trial investigat...

Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab as the First-line Treatment for Patients with NSCLC at Annual Meeting of the Chinese Society of Clinical Oncology

SUZHOU, China, Sept. 20, 2018 /PRNewswire/ -- Innovent Biologics (Innovent), a world-class China-based biopharmaceutical company that develops and commercializes high quality drugs, today presented clinical trial data on cohort D of sintilimab clinical studies at the 2018 Annual Meeting of Chinese Society of Clinical Oncology (CSCO). In this phase 1b clinical trial (NCT02937116) patients suff...

4SC AG: Domatinostat plus chemotherapy - Overcoming drug resistance

DGAP-News: 4SC AG / Key word(s): Conference 20.09.2018 / 07:30 The issuer is solely responsible for the content of this announcement. 4SC AG: Domatinostat plus chemotherapy - Overcoming drug resistance Domatinostat (4SC-202) renders cancer cell lines more susceptible to chemotherapy treatment Poster presentation at the SIC Annual Meeting, 19-22 September 2018, Milan, Italy   ...

Wednesday 19th September 2018

Novartis Diabetes Triple Drug Combination Deemed 'Irrational' In India

Novartis’s plans for triple drug diabetes combination which includes vildagliptin have been turned down in India at least for now...   

Patient Experience Data: US FDA’s Evidentiary Standards Should Reflect Intended Use

Degree of rigor may vary depending upon intended use of the data throughout a drug’s lifecycle, stakeholders say in comments...   


In a decisive action to weed out irrational, unscientific and hazardous drugs from the country's pharmaceutical market, the Union Health Ministry has banned the controversial 328 Fixed Dose Combination drugs with immediate effect in the country.

Will CBO Score CREATE Momentum For Generic Bill's Passage?

Strong savings estimate – and brand pharma's need to have pay-fors for its own legislative priorities – could finally get bill allowing generic...   

Novel deep learning drug discovery platform gets £1 million innovation boost

September 19, 2018 - Funding to support Artificial Intelligence (AI) in drug discovery takes a significant step forward today as Optibrium™, Intellegens, and Medicines Discovery Catapult secure a grant from Innovate UK to fund a £1 million project. The program will see Optibrium, which creates software to improve the efficiency and productivity of drug discovery, and Intellegens...

SenzaGen launches the first in vitro airway allergy test – GARDair – at ESTIV2018

Lund, September 18, 2018 - SenzaGen (Nasdaq First North: SENZA) announced today that the company will launch GARDair, the first in vitro test for airway allergies at ESTIV2018, the 20th International Congress on In Vitro Toxicology. Removing the need for animal testing and opening a completely new market, GARDair is based on the company’s proprietary GARD® technology platform. Using ge...

Tuesday 18th September 2018

Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder Cancer

Bavarian Nordic-sponsored study has commenced dosing Study marks the second of three planned Phase 2 combination studies of CV301 with checkpoint inhibitors in solid tumors COPENHAGEN, Denmark, September 18, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the first patient has been dosed in a Phase 2 study evaluating the combination therapy of its cancer imm...

DFB Soria Completes a Phase 2 Clinical Trial of Submicron Particle Paclitaxel Anhydrous Ointment for Actinic Keratosis

Soria investigational drug provides evidence of actinic keratosis (AK) lesion reduction without the local irritation of approved topical AK treatment products DFB Soria, a DFB Pharmaceuticals company, today announced completio

Monday 17th September 2018

Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro

Drug resistance of paclitaxel (TAX), the first-line chemotherapy drug for breast cancer, was reported to develop in 90% of patients with breast cancer, especially metastatic breast cancer. Investigating the me...

IMV Inc. Announces Early Positive Results from Phase 2 Clinical Trial of Lead Candidate DPX-Survivac in Combination with Merck’s Keytruda® in Patients with DLBCL

DARTMOUTH, Nova Scotia, Sept. 18, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced details of the initial data from an ongoing investigator-sponsored Phase 2 clinical trial. In the study, investigators are evaluating IMV’s lead candidate, DPX-Survivac, in combination with low dose cyclophosphamide and Merck’s checkpoint...

Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 & THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria

Leuven, Belgium, 17 September 2018 - Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today that it will give two presentations at the Euretina International Congress, which is being held in Vienna, Austria, from 20...

OV - Updated LiPlaCis data positions LiPlaCis and its DRP for an FDA Breakthrough Therapy designation application for breast cancer

Hoersholm, Denmark, September 17, 2018 - Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) ("OV" or "the Company") announce the fourth update from the ongoing LiPlaCis® Phase 2 study. In the ongoing study, the data points to the possibility of obtaining a Breakthrough Therapy designation by the FDA. In the LiPlaCis DRP top tier group (1/3) of highest l...

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine...

Sunday 16th September 2018

SUN $MEIP MEI Pharma (MEIP, $12, BUY) — Dec 1-4 at ASH — Updated Discontinuation Rate Important for Efficacy in Combination Pracinostat with Azacitidine in MDS

SUN $MEIP MEI Pharma (MEIP, $12, BUY) — Dec 1-4 at ASH — Updated Discontinuation Rate Important for Efficacy in Combination Pracinostat with Azacitidine in MDS

Friday 14th September 2018

How ROS affects cisplatin resistance in ovarian cancer cells

Long-term use of anti-cancer drugs treatment may lead to the development of multiple drug resistance reducing the efficiency of chemotherapy. Scientists are aware of several mechanisms for drug resistance development in tumour cells. They are to a great...

Innate Pharma reports first half 2018 financial results and business update

InNate Pharma REports first Half 2018 Financial Results and Business Update Preliminary anti-tumor activity for lead asset, monalizumab, in combination with cetuximab in advanced head and neck cancer and durvalumab in microsatellite-stable colorectal cancer presented at medical conferences Recruiting additional patients into the cohort expansion for monalizumab in combination ...


Phase 3 Clinical Trial Data Show Efficacy of BARHEMSYS in Treatment of Post-Operative Nausea & Vomiting Cambridge, UK and Indianapolis, US - 14 September 2018: Acacia Pharma Group plc ("Acacia Pharma", the "Company") (EURONEXT: ACPH) announces that data and analyses from its positive Phase 3 clinical trial with BARHEMSYS(TM) (intravenous amisulpride) have...

Wednesday 12th September 2018

Helix BioPharma Corp. Initiates Enrollment of the Second Last Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

RICHMOND HILL, Ontario, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Safety Review Committee ("SRC") reviewed safety data from the fifth dosing cohort of the Company’s LDOS001 study and recommended that He...

RUDN biochemists found out how ROS affect cisplatin resistance in ovarian cancer cells

(RUDN University) A team of sciences from RUDN Institute of Medicine found out how reactive oxygen species affect the resistance of ovarian cancer cells to chemotherapy on the example of cisplatin -- an antitumor drug used to treat this type of malignant growth. Practical application of the research results would help improve medical treatment schemes for cancer patients. The article of the scient...

Combination Treatment Targets Pre-Leukemia Stem Cells

NewsThe study shows that MDS stem cells dramatically increase their energy use and production of proteins. Contributed Author: 

Infraredx to Present Results of the Lipid-Rich Plaque (LRP) Study at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Scientific Symposium

The highly anticipated study results will be presented at a late-breaking clinical trial session at TCT on Monday, September 24 Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, today announced that results from the highly anticipated Lipid-Rich Plaque (LRP) Study have been accepted as a late-breaking clinical tri...

Quick Search


News Quicklinks